Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
- Status
- Accepting Candidates
- Ages
- 40 Years - N/A
- Sexes
- All
Idiopathic pulmonary fibrosis (IPF) is scarring or thickening of the lungs without a known cause.
Idiopathic diffuse interstitial pulmonary fibrosis; IPF; Pulmonary fibrosis; Cryptogenic fibrosing alveolitis; CFA; Fibrosing alveolitis; Usual interstitial pneumonitis; UIP
Health care providers do not know what causes IPF or why some people develop it. Idiopathic means the cause is not known. The condition may be due to the lungs responding to an unknown substance or injury. Genes may play a role in developing IPF. The disease occurs most often in people between 60 and 70 years old. IPF is more common in men than women.
When you have IPF, your lungs become scarred and stiffened. This makes it hard for you to breathe. In most people, IPF gets worse quickly over months or a few years. In others, IPF worsens over a much longer time.
Symptoms may include any of the following:
The provider will do a physical exam and ask about your medical history. You will be asked whether you have been exposed to asbestos or other toxins and if you have been a smoker.
The physical exam may find that you have:
Tests that help diagnose IPF include the following:
There is no known cure for IPF.
Treatment is aimed at relieving symptoms and slowing disease progression:
Making home and lifestyle changes can help manage breathing symptoms. If you or any family members smoke, now is the time to stop.
A lung transplant may be considered for some people with advanced IPF.
You can ease the stress of illness by joining a support group. Sharing with others who have common experiences and problems can help you not feel alone.
More information and support for people with IPF and their families can be found at:
IPF may improve or stay stable for a long time with or without treatment. Most people get worse, even with treatment.
When breathing symptoms become more severe, you and your provider should discuss treatments that prolong life, such as lung transplantation. Also discuss advance care planning.
Complications of IPF may include:
Contact your provider right away if you have any of the following:
National Heart, Lung, and Blood Institute website. Idiopathic pulmonary fibrosis. www.nhlbi.nih.gov/health/idiopathic-pulmonary-fibrosis. Updated March 24, 2022. Accessed May 26, 2022.
Raghu G, Martinez FJ. Interstitial lung disease. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 86.
Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-e19. PMID: 26177183 pubmed.ncbi.nlm.nih.gov/26177183/.
Ryu JH, Selman M, Lee JS, Colby TV, King TE. Idiopathic pulmonary fibrosis. In: Broaddus VC, Ernst JD, King TE, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 7th ed. Philadelphia, PA: Elsevier; 2022:chap 89.
Silhan LL, Danoff SK. Nonpharmacologic therapy for idiopathic pulmonary fibrosis. In: Collard HR, Richeldi L, eds. Interstitial Lung Disease. Philadelphia, PA: Elsevier; 2018:chap 5.
UF Health research scientists make medicine better every day. They discover new ways to help people by running clinical trials. When you join a clinical trial, you can get advanced medical care. Sometimes years before it's available everywhere. You can also help make medicine better for everyone else. If you'd like to learn more about clinical trials, visit our clinical trials page. Or click one of the links below:
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550 (study…
Imagine having the opportunity to save someone’s life by making a simple decision. In 2021, Danny Sams faced the harsh reality of pulmonary fibrosis, a lung…
June 7, 2018
University of Florida Health has been designated a member of the Pulmonary Fibrosis Foundation’s Care Center Network, making it one of just 60 medical centers…
Department of Medicine, +3 more